Pharmaceuticals

Abbott's premier global pharmaceutical business is dedicated to discovering, developing and marketing breakthrough drugs that improve patient health. Our primary focus is on translating innovative science into effective medicine to address unmet medical needs.

We've made key acquisitions that have brought us rich pipelines and outstanding technologies for the future. For example, Humira was acquired in the Knoll Pharmaceuticals acquisition in 2001. Partnerships such as this one have helped us further build our pharmaceutical expertise and capabilities, while also helping the partnering organizations accomplish their goals. A sample listing of some of our successful partnerships follows.

Product	Originated From	Area of Expertise
	Knoll	Immunology	Safety Information Prescription Information
	KOS	Cardiovascular	Safety Information Prescription Information
	KOS	Cardiovascular	Safety Information Prescription Information
	Fournier/Solvay	Cardiovascular	Safety Information Prescription Information
	Knoll	Metabolics	Safety Information Prescription Information
	Maruishi	Anesthesia	Safety Information Prescription Information
	Sanofi-Aventis	Neuroscience	Safety Information Prescription Information
	Taisho	Anti-infectives	Prescription Information
	Astellas	Anti-infectives	Prescription Information
	MedImmune	Immunology	Safety Information Prescription Information
	WARF	Renal Care	Safety Information Prescription Information

Research Collaborations (sample listing)
	Dharmacon	Oncology
	Enanta	Virology
	Genentech	Oncology

Printer Friendly